The use of MRI-based monitoring can aid in the avoidance of repeat biopsies, and reduce the chances of undergoing surgery.
Prostate Cancer Diagnostics
Advertisement
Latest News
John P. Sfakianos, MD, discusses the history and use of ctDNA in the GU oncology field.
Maximizing Benefits and Minimizing Harm: Reviewing AUA Guidelines on Prostate Cancer Early Detection
Dr. Salami explains how updated guideline approaches shared decision-making in higher-risk groups.
Dr. Hong reviews relevant key findings from clinical trials for oligometastatic disease.
Dr. Hong reviews the criteria used to determine which patients may benefit from MDT.
Dr. Chu highlights how PSMA PET is transforming perioperative prostate cancer care, including improving surgical precision.
Dr. Hope evaluates PSMA PET vs SPECT imaging for tracking therapy response in prostate cancer.
Prostate Cancer Knowledge Hubs
Curated clinical content on prostate cancer types, therapies, and technologies
Conference Coverage
Dr. Tagawa explains the rationale for EVOLUTION, a phase II analysis of Lu-PSMA-617 with ipilimumab and nivolumab in mCRPC.
Dr. Tagawa contextualizes a post hoc analysis on clonal hematopoiesis in those who received 177Lu-PSMA-617 or cabazitaxel.
Dr. Tagawa showcases the ProstACT Global trial, a phase III study of 177Lu-rosptamab in patients with mCRPC.
Dr. Tagawa breaks down the VIOLET study, a single-arm phase I/II first-in-human results of terbium-161Tb-PSMA-I&T.
Dr. McGregor shares the opening of the STRIKE trial, which investigates adding tivo to pembro in the mRCC adjuvant setting.
Dr. McGregor opens up about the expansion cohort of the phase 1 ARC-20 study, which looked at casdatifan plus cabozantinib.
Advertisement
Advertisement
Trending
Dr. Tagawa explains the rationale for EVOLUTION, a phase II analysis of Lu-PSMA-617 with ipilimumab and nivolumab in mCRPC.
Dr. Tagawa contextualizes a post hoc analysis on clonal hematopoiesis in those who received 177Lu-PSMA-617 or cabazitaxel.
Dr. Tagawa showcases the ProstACT Global trial, a phase III study of 177Lu-rosptamab in patients with mCRPC.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.